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Abstract
The incidence of malignant melanoma is rising worldwide and survival for metastatic disease is still poor.
Recently, new treatment options have become available. Still, predictive biomarkers are needed to optimise treat-
ment for this patient group. In this study, we investigated the predictive value of 60 angiogenic factors in
patients with metastatic melanoma treated with the anti-vascular endothelial growth factor A antibody bevaci-
zumab. Thirty-five patients were included in a clinical phase II trial and baseline serum samples were analysed by
multiplex protein array. High-serum concentration of Activin A was significantly associated with objective
response (OR) to treatment (p = 0.014). Candidate proteins that indicated a borderline association with treat-
ment response were further investigated by immunohistochemistry. Strong expression of Activin A, interleukin-
1β, and urokinase-type plasminogen activator receptor in metastases was significantly associated with OR
(p = 0.011, p = 0.003, and p = 0.007, respectively), as well as with markers of activated angiogenesis, such as
higher number of proliferating vessels and the presence of glomeruloid microvascular proliferations. Our findings
indicate that these proteins may be potential predictive markers for treatment with bevacizumab monotherapy.
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Introduction
New treatment options have recently become available
for patients with metastatic melanoma, and
progression-free survival (PFS) [1,2] and overall sur-
vival (OS) [3,4] have improved substantially. Combi-
nation of different types of immune checkpoint
inhibitors is the most promising approach with high-
response rates [5,6]. However, limitations such as
acquired resistance are recorded for BRAF inhibitors
[1], and moderate survival benefits are observed for
the CTLA4 antibody ipilimumab [3]. At the same
time, incidence rates of malignant melanoma are
increasing worldwide among fair-skinned populations,
and the 5-year survival rate in metastatic melanoma is
poor [7]. Thus, there is a persisting need to identify
alternative treatment options for such patients.
Validated predictive markers are urgently needed to
optimise treatment, avoid side-effects of ineffective
treatment, and improve funding of expensive cancer
drugs within public healthcare systems.
Angiogenesis is a known hallmark of cancer [8] and
is also involved in melanoma progression [9] and
metastasis [10,11]. Furthermore, high vascularity in
primary melanomas is an adverse prognostic marker
[12–14]. Vascular endothelial growth factor A (VEGF-
A) is one of the important angiogenesis growth factors
and seems also to promote an immunosuppressive pro-
tumourigenic environment [15]. Several clinical trials
that combine anti-angiogenic treatment and immuno-
therapy are currently under investigation. Bevacizu-
mab, a monoclonal antibody against VEGF-A, is
approved for various solid tumours in combination
with chemotherapy. We performed a clinical phase II
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study with bevacizumab monotherapy in patients with
metastatic melanoma and observed an objective
response (OR) rate of 17%, i.e. patients with complete
or partial response, as well as a disease control rate of
31%, i.e. including patients with stable disease for at
least 6 months [16]. The addition of bevacizumab to
chemotherapy showed promising activity in previous
phase II studies for advanced or metastatic melanoma
[17–19]. Although biomarker analyses have been per-
formed on blood samples from patients with various
tumour types treated with bevacizumab in randomised
studies, no predictive markers have yet been estab-
lished for clinical use [20,21]. In the present study, we
investigated the predictive value of 60 angiogenesis-
related factors in pre-treatment serum samples. To the
best of our knowledge, we are the first to report that
the serum concentration of Activin A is associated
with OR. For further validation, intra-tumoural expres-
sion of candidate proteins was investigated by immu-
nohistochemistry. Strong expression of Activin A,
interleukin-1β (IL1β), and uPAR in melanoma metas-
tases was correlated with response to bevacizumab
treatment.
Methods
Patients and study design
Thirty-five patients with metastatic melanoma were
included in a clinical phase II study at Haukeland Uni-
versity Hospital, Norway, and treated with bevacizumab
monotherapy until disease progression or intolerable
toxicity (ClinicalTrials.gov: NCT00139360). The study
design, patient characteristics, eligibility criteria, and
response data were described previously [16]. Treat-
ment response was assessed in accordance to RECIST
guidelines. Response data were updated on July
31, 2018. OR was defined as complete or partial
response and reported in 7 of 35 patients; 4 additional
patients had stable disease. In total, 31% had disease
control from this treatment as published previously
[16]. Median PFS was 2.1 months (range 0.4–
132 months) and median OS was 9.3 months (range
1.1–132 months). The study was approved by the
Regional Ethics Committee (processing number:
05/329) and the Norwegian Medicines Agency and con-
ducted according to the ethical principles of the Decla-
ration of Helsinki and the International Conference on
Harmonization of Good Clinical Practice. All patients
signed informed consent before enrolment.
Tissue and blood samples
Paraffin embedded tissue from 30 of 35 primary
tumours and 35 of 35 metastases was available for
investigations. Three of five missing primary melano-
mas were described earlier [22]; two additional mela-
nomas had to be excluded because of insufficient
material. The metastasis diagnosed closest to inclusion
in the study was used for immunohistochemical stain-
ing. Detailed information about the tissues available
from metastases has been reported [22].
Serum samples taken before the start of bevacizumab
treatment were available in 28 patients. The samples
were taken within 13 days before the first treatment
(median 2 days). All samples were processed as reported
[22]. The aliquoted samples were stored at –80 C.
Multiplex angiogenesis array
The Quantibody Human Angiogenesis Array 1000
(RayBiotech Inc., Norcross, GA, USA) was used for
analysis of 60 angiogenesis-related proteins (supplemen-
tary material, Table S1). This array is based on the
sandwich enzyme-linked immunosorbent assay
(ELISA)-technology, and each antibody is spotted in
quadruplicate. The procedure was performed at room
temperature. First, all wells were blocked with sample
diluent. Then, the array was incubated with serum sam-
ples and the standard dilutions for 2 h. The washing pro-
cess was followed by incubation with the detection
antibody for 2 h. After further washing, Cy3 equivalent
was added to each well and incubated for 1 h. Imaging
was performed by a microarray scanner (GenePix 4000B,
Axon Instruments, San Jose, CA, USA) at different
photomultiplier tube gains. Interslide normalisation for
the most suitable scan was performed by RayBiotech
(Norcross, GA, USA). The concentrations based on linear
standard curves were used for further analyses.
Immunohistochemistry
Tissue sections of 4–5 μm were used for immunohisto-
chemical staining with primary antibodies against
Activin A (Sigma–Aldrich, St. Louis, Missouri,
USA, A1594), IL1β (Santa Cruz Europe, Heidelberg,
Germany, sc-7884), and uPAR (American Diagnostics,
New York, USA, ADG3937). In brief, sections were
deparaffinised in xylene and different alcohol dilutions
and rehydrated before antigen retrieval was performed by
microwave heating. After blocking with a peroxidase
inhibitor, the primary antibody was added. 3-Amino-9-
ethylcarbazole was used as chromogen for all staining.
Further details are provided in Table 1. Primary anti-
bodies were omitted for negative controls; normal tissue
and different cancer types were used as positive controls.
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The intra-tumoural expression of VEGF-A, heat
shock protein 27 (HSP27), and basic fibroblast growth
factor (bFGF) as well as microvessel density [23], the
number of proliferating vessels [24] and the presence
of glomeruloid microvascular proliferations (GMPs)
[25] were presented previously [22] and included here
for comparison. Furthermore, histopathological fea-
tures and clinical parameters that were described
earlier were included in the present analyses [16,22].
Evaluation of staining results
The immunohistochemical staining in the cytoplasm of
tumour cells was evaluated using a light microscope. The
slides were screened at low magnification (×100), stain-
ing intensity and area were finally investigated at magni-
fication ×200 and recorded using a semi-quantitative
grading. Staining intensity was graded as absent (0),
weak (1), moderate (2), or strong (3). The proportion
(area) was assessed as ‘no positive tumour cells’ (0), ‘less
than 10% positive tumour cells’ (1), ‘10–50% positive
tumour cells’ (2), or ‘more than 50% positive tumour
cells’ (3). The staining index (SI) is the product of inten-
sity and area with a range from 0 to 9; SI was rated by
two observers (CS, OS) blinded for response data.
Statistical analysis
The final serum concentrations of the multiplex analysis
were normalised by log2 and quantile normalised in the
R/Bioconductor environment [26]. Dixon test was per-
formed to detect outlier samples. First, unsupervised
analysis using Ward hierarchical clustering and heat map
diagram was performed. Then supervised analysis was
performed for particular proteins. The fold change
(FC) between responders and non-responders was calcu-
lated based on median concentrations (significance
thresholds ≤0.82 and >1.25). Mann–Whitney test
(MWT) was computed using Wilcoxon test function in
the R/Bioconductor programming environment to detect
differences in protein expression between the samples
[27]. The boxplots were consistent with the statistical
results. Correction for multiple testing was not per-
formed; instead, candidate proteins were validated by
immunohistochemistry. Further statistical analyses were
performed with SPSS, version 22 (SPSS Inc., Chicago,
IL, USA). Quantile normalised data were used for protein
concentrations assessed by the multiplex array. MWT
was used to identify correlations between interval or ordi-
nal scaled variables and categorical variables. Correla-
tions between two interval scaled variables or an interval
and an ordinal scaled variable were calculated by Spear-
man’s rho correlation. Associations between related sam-
ples such as protein expression in primary melanomas
and metastases were investigated by paired-MWT
(pMWT). Kaplan–Meier survival curves were used to
investigate PFS; significance differences between the
groups were calculated by the log-rank test. The date of
inclusion was defined as the start point and the date of
confirmed disease progression or July 31, 2018 as the
end point. The median was used as cut-off point if not
defined differently. The significance threshold for all tests
was 0.05. Non-parametric tests were used since not all
data were normal distributed. Significant P values are
given for all associations assessed by MWT. pMWT is
added to the P values when paired analyses were per-
formed. Spearman’s rho (r) and the corresponding
P value are given for calculations of correlations. Immu-
nohistochemical markers correlated to response were
combined in a signature. The signature was calculated by
the mean SI of the markers of interest [28,29]. Receiver
operating characteristic (ROC) curves [30] were per-




Analysis of 60 angiogenesis-related factors in serum sam-
ples was performed to identify possible predictive markers
for treatment with bevacizumab monotherapy in patients
with metastatic melanoma. After exclusion of outliers
Table 1. Immunohistochemical staining methods
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based on the Dixon test, 25 of 28 serum samples were
included in the final analyses. Unsupervised hierarchical
clustering did not show any distinct patterns or global
differences between samples (supplementary material,
Figure S1). The association between each single protein
concentration and OR was calculated. Proteins with a FC
threshold ≤0.82 and >1.25 between patients with OR and
progressive disease (PD) as well as a P value <0.2 were
Activin A, AgRP, IL1β, uPAR, VEGF-A, IL-12p40, and
LIF (Leukaemia inhibitory factor) (Table 2). Based on
our objective to assess predictive markers in patients
treated with an anti-VEGF-A antibody, we focused on
Activin A, IL1β, uPAR, and VEGF-A in further investi-
gations, since all of these proteins are known to be
involved in VEGF-A-related angiogenesis. The FC of
Activin A was 3.29 in patients with OR to bevacizumab
compared to non-responders (p = 0.014; Figure 1A).
High serum concentration was correlated with treatment
response. The ROC curve for Activin in serum shows an
area under the curve of 0.813 (see supplementary mate-
rial, Figure S2). Median serum concentrations of IL1β,
uPAR, and VEGF-A were lower in patients who had OR
to bevacizumab monotherapy (p = 0.178, p = 0.141, and
p = 0.110; Figure 1B,D). High concentration of uPAR
correlated with high concentration of VEGF-A (r = 0.40,
p = 0.047). There was no significant correlation between
serum concentrations of Activin A, IL1β, uPAR, or
VEGF-A and microvessel density, the number of prolif-
erating vessels, or the presence of GMPs in metastatic
tumour tissue. Protein concentrations measured by multi-
plex array are given in supplementary material, Table S2.
Immunohistochemistry
For further validation, protein expression of Activin A,
Il1β, and uPAR was examined in primary tumours and
metastases by immunohistochemistry.
Table 2. Candidate proteins that differ between responders and
non-responders to bevacizumab monotherapy
Protein Fold-change P value (Mann-Whitney test)







Fold-changes are calculated based on median serum concentrations measured
by multiplex array. Proteins with fold-change threshold ≤0.82 and >1.25 and
corresponding P values <0.2 are listed. LIF, Leukaemia inhibitory factor.
Figure 1. Associations between serum concentration of candidate proteins measured by multiplex array and objective response (OR) to
bevacizumab monotherapy in patients with metastatic melanoma. Mann-Whitney test was used to calculate the difference in concentration
between patients with OR and progressive disease (PD). FC, fold change.
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Positive cytoplasmic staining for Activin A was
observed in 25 of 29 primary tumours and 22 of
32 metastases (Figure 2A,B). The median SI was 2 in
primary melanomas and metastases, and median SI
was significantly higher in metastases from patients
with OR to bevacizumab monotherapy compared with
patients with PD (SI 3 versus SI 2, p = 0.011;
Figure 3A). The ROC curve shows an area under the
curve of 0.809 and a cut off value of 2.5 (sensitivity:
0.857, 1 − specificity: 0.280) (supplementary material,
Figure S2). Activin A expression in metastases
correlated with a higher number of proliferating
Figure 2. Immunohistochemical staining of candidate proteins in tumour cells. (A) Intermediate expression of Activin A. (B) Negative
staining for Activin A. (C) Strong and (D) weak expression of IL1β. (E) Strong and (F) weak expression of uPAR. (G) Strong and (H) weak
expression of VEGF-A.
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microvessels (r = 0.44, p = 0.012) and the presence of
GMPs in metastases (p = 0.001). Additionally, strong
expression of Activin A in metastases correlated with
strong cytoplasmic expression of HSP27 (r = 0.36,
p = 0.043), VEGF-A (r = 0.49, p = 0.005), and bFGF
(r = 0.59, p < 0.001). Immunohistochemical expres-
sion of Activin A in metastases did not correlate
significantly with Activin serum concentration mea-
sured by multiplex array.
IL1β was expressed in the cytoplasm of 28 of 30 pri-
mary tumours and in 20 of 33 metastases (Figure 2C,
D). The median SI was significantly higher in primary
melanomas compared to metastases in which staining
was absent in 40% of the cases (SI 3 versus SI
Figure 3. Association between intra-tumoural expression of candidate proteins and objective response (OR) to bevacizumab monotherapy
in patients with metastatic melanoma. Mann-Whitney test was used to calculate the difference in staining indices between patients with
OR and progressive disease (PD). A, activin A; B, IL1β; C, uPAR; D, VEGF-A; E, immunohistochemistry (IHC) signature score.
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2, p = 0.032; pMWT). IL1β expression in metastases
was significantly stronger in patients with OR to beva-
cizumab monotherapy (SI 3 versus 0.5, p = 0.003;
Figure 3B). The ROC curve shows an area under the
curve of 0.854 and a cut-off value of 2.5 (sensitivity:
0.714, 1 − specificity: 0.154) (supplementary material,
Figure S2). A higher number of proliferating vessels
and the presence of GMPs was seen in metastases with
strong expression of IL1β (r = 0.43, p = 0.015, respec-
tively; p = 0.034). Strong IL1β expression in metasta-
ses correlated with strong expression of VEGF-A,
bFGF, and Activin A (r = 0.42, p = 0.016; r = 0.62,
p < 0.001; and r = 0.77, p < 0.0005). IL1β concentra-
tion measured by the multiplex array did not correlate
significantly with IL1β expression in metastases.
Twenty-eight of the 30 primary tumours and 28 of
34 metastases showed cytoplasmic staining for uPAR
(Figure 2E,F). uPAR expression in primary melano-
mas was significantly stronger than in metastases
(median SI 3.5 versus 2, p = 0.017; pMWT). Metasta-
ses in patients with OR to bevacizumab showed signif-
icantly stronger expression of uPAR than those of
non-responders (SI 4 versus 2, p = 0.007, Figure 3C).
The ROC curve shows an area under the curve of
0.823 and a cut-off value of 2.5 (sensitivity: 0.857,
1 − specificity: 0.259) (supplementary material,
Figure S2). Strong expression of uPAR in metastases
was associated with higher microvessel density and a
higher number of proliferating vessels in metastases
(r = 0.41, p = 0.018; r = 0.38, p = 0.027). Addition-
ally, the SI for uPAR was higher in metastases with
GMPs (SI 5 versus SI 2, p = 0.021). Strong uPAR
expression correlated with strong HSP27, Activin A,
and IL1β staining in metastases (r = 0.52, p = 0.002;
r = 0.65, p < 0.001; and r = 0.62, p < 0.001 respec-
tively). The expression of uPAR, VEGF, and bFGF in
metastases was not correlated. uPAR expression in
metastases did not correlate with serum concentration
of uPAR measured by the multiplex array.
Cytoplasmic staining of VEGF-A (Figure 2G,H) in
metastases was not associated with response to bevaci-
zumab, although it did correlate with higher microves-
sel density [22]. VEGF-A concentration in serum
samples was not associated with immunohistochemical
expression of VEGF-A in metastases [22].
The staining indices of Activin-A, IL1β, and uPAR
were combined in a signature (IHC signature). Patients
with a high IHC signature score had significantly better
response to treatment with bevacizumab (median score
3.0 versus 1.3, p < 0.000, MWT; Figure 3E). The ROC
curve shows an area under the curve of 0.920 and a
cut-off value of 2.5 (sensitivity: 1.0; 1 − specificity:
0.08) (supplementary material, Figure S2).
Discussion
Anti-angiogenic treatment with bevacizumab has been
an established treatment option for various tumours
since its approval in 2004. Its role in treatment of met-
astatic melanoma is still under investigation. Angio-
genesis is a complex process regulated by the
interplay of many different growth factors, cytokines,
and interactions with the microenvironment [31] which
makes it challenging to identify single proteins as pre-
dictive factors. No attempt to establish validated pre-
dictive biomarkers for treatment with bevacizumab has
been successful to this day [20,21]. Biomarker studies
have mostly been performed on blood or tissue sam-
ples from patients receiving bevacizumab in combina-
tion with chemotherapy versus chemotherapy alone.
Conversely, our material is from a clinical trial with
bevacizumab monotherapy which was performed to
investigate response rates and potential predictive
markers of response in patients with metastatic mela-
noma. Overall, 7 of 35 patients (20%) had complete or
partial response [16]. Based on the promising results
in a patient group with otherwise poor prognosis, we
investigated potential predictive factors in tissues and
serum samples.
Strong uPAR expression in metastases at baseline
was associated with OR to bevacizumab monotherapy.
In addition, we observed a significant correlation
between strong expression of uPAR in metastases and
a higher number of microvessels, proliferating vessels,
and GMPs supporting the relevance of uPAR for
tumour-associated angiogenesis. uPAR is expressed to
a higher extent in various kinds of tumour compared
to normal tissues [32]. In melanoma, uPAR expression
is stronger in more advanced primary lesions and met-
astatic melanoma compared to thin melanomas or nevi
[33]. uPAR is an important player in extracellular
matrix degradation, cell motility, invasion, prolifera-
tion, and cell survival, and it is involved in multiple
intra-cellular signalling pathways [34]. Furthermore,
VEGF-A-induced re-localisation of uPAR to the lead-
ing edge of migrating endothelial cells promotes
angiogenesis [35] in addition to its proteolytic func-
tion. Our findings indicate that patients with strong
uPAR expression in metastases and activated angio-
genesis may benefit from treatment with bevacizumab.
Loss of uPAR expression in metastases may character-
ise clones of metastases which do not depend on
angiogenesis to the same extent [36]. In our view,
uPAR is a promising predictive marker for treatment
with bevacizumab in melanoma patients.
IL1β is produced by tumour cells, macrophages, and
myeloid derived cells; it is absent in homeostatic
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conditions and plays an important role in immune
response and tumour-mediated angiogenesis [37].
Here, we found that strong IL1β expression in metasta-
ses correlated with OR to treatment with bevacizumab
monotherapy. In addition, strong IL1β expression in
metastases correlated with a higher number of prolifer-
ating vessels and strong cytoplasmic expression of
VEGF-A and bFGF in metastatic lesions. These obser-
vations are in line with findings indicating interactions
between IL1β, VEGF-A, bFGF, and endothelial cells
in angiogenesis [37,38]. IL1β produced by tumour
cells recruits myeloid cells and stimulates them to
secrete pro-angiogenic proteins; in addition, IL1β acti-
vates expression of VEGF-A, and other angiogenic
cytokines in endothelial cells and influences migration
and tube formation [37]. Carmi et al reported cross-
talk between VEGF-A and IL1β during angiogenesis
in a model of B16 melanoma cells [39]. In IL1β KO
mice, limited angiogenesis was seen and the number
of VEGF-producing cells was reduced. These findings
demonstrate an importance of IL1β for induction of
VEGF-A dependent angiogenesis. In line with this, we
observed an association between expression of IL1β
and pro-angiogenic proteins as well as vessel density,
and response to bevacizumab.
High concentration of Activin A in serum samples
correlated strongly with OR to bevacizumab mono-
therapy. In line with this, Bai et al found a significant
correlation between high Activin A concentration in
plasma samples and better PFS in patients with colo-
rectal cancer treated with chemotherapy and bevacizu-
mab [40]. Furthermore, we found an association
between strong expression of Activin A in metastases
and OR. Activin A expression also correlated with the
presence of the pro-angiogenic markers VEGF-A,
bFGF, and HSP27 as well as a higher number of pro-
liferating vessels in metastases. Others reported that
Activin A induced VEGF-A and bFGF expression
in vitro and observed increased tubulogenesis when
Activin A and one of these angiogenic proteins were
added simultaneously [41,42]. Activin A stimulated
VEGF-A expression in various tumour cell lines [43],
corneal epithelial cells, and when using an in vivo
model of corneal neovascularisation [44].
VEGF-A is one of the key pro-angiogenic proteins
in growing tumours [45,46]. However, the level of
expression in metastases did not predict response to
treatment with the anti-VEGF antibody bevacizumab
[22]. Increased serum concentration of VEGF-A is
reported to predict reduced survival in patients with
melanoma [47], colorectal cancer [48], and ovarian
cancer, indicating prognostic value [49]. The role of
VEGF-A as a predictive marker for response to
bevacizumab has been examined in previous studies in
different cancer types [20,21]. The complexity of
angiogenesis and the heterogenous effects of VEGF
inhibition on tumours make investigation of predictive
biomarkers challenging. There is still a lack of such
markers as a decision-making tool for anti-VEGF
treatment [20,50].
Serum concentrations and tissue expression of uPAR,
IL1β, Activin A, and VEGF-A were not correlated in
our material. These findings are in line with other
reports on a discrepancy between serum and tissue con-
centrations for uPAR [51]. Woods et al measured low
concentrations of IL1β in supernatants from squamous
cancer cell lines that expressed intra-tumoural IL1β
[52]. Also, in ovarian cancer, VEGF-A expression did
not correlate with serum concentration as recently pub-
lished [49]. Others reported an inverse correlation
between local and systemic levels of VEGF-A during
angiogenesis in wound healing. Differences in intra-
and extra-tumoural protein expression may be explained
by complex tumour–stroma interactions and reflect the
challenge to identify robust biomarkers. In addition, the
soluble form of proteins is investigated in serum sam-
ples whereas cellular surface receptors or intra-cellular
proteins are detected by immunohistochemistry. As dis-
cussed by Komatsu et al [49], intra- and inter-tumoural
heterogeneity may partly explain the lack of association
between the protein expression in one single biopsy and
the serum concentration.
Conclusion
We identified uPAR, IL1β, and Activin A as potential
predictive markers for objective response to treatment
with bevacizumab monotherapy in metastatic mela-
noma. In particular, a high score in the IHC signature
including expression of Activin A, IL1β, and uPAR in
metastases correlated significantly with treatment
response. In addition, the serum concentration of Acti-
vin showed promising results. The role of these proteins
as predictors in anti-VEGF-A treatment should be fur-
ther investigated. Our results shed light on the complex
interplay between VEGF-A, as the target of bevacizu-
mab, on the one side and other proteins involved in
angiogenesis and inflammation on the other.
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